Abstract:Background: Neoadjuvant chemotherapy (NCT) has become an important part in the comprehensive treatment of breast cancer, patients classified with pathological complete remission (pCR) after NCT have superior outcome. A single center, prospective phase II study was initiated to evaluate the activity and safety of non-anthracycline-containing weekly PCb regimen in NCT for breast cancer, which may help our further clinical usage and research.Materials and Methods: Eligible patients with clinical stage IIA∼IIIC breast cancer were assigned to receive four cycles of PCb with the dose of P (Paclitaxel) 80mg/m2 and Cb (Carboplatin) AUC=2, given day 1, day 8 and day 15, out of every 4 weeks. Clinical response and extent of residual disease in breast and axillary lymph nodes (ALN) in surgical removed sample were assessed after completion of NCT. pCR was defined as no invasive cancer in breast and axillary. Estrogen(ER), Progesterone (PR) receptor and HER2 status were detected before treatment by immunohistochemistry, HR (hormonal receptor) was defined positive as either or both ER/PR positive.Results: From Dec. 2007 to Dec. 2008, 107 breast cancer patients received weekly PCb NCT and one with bilateral breast cancer. 85.2% patients were initially diagnosed with stage III diseases, 83 patients had positive ALN confirmed by fine needle aspiration before NCT. 94.4% (102) patients have completed all of 4 cycles weekly PCb treatment. Clinical response rate was 86.1% with clinical complete remission rate 32.4%. 21 patients achieved pCR, with pCR rate 19.4%. 30 cases who had positive ALN before NCT showed negative result in the surgery specimen with ALN downstage rate 36.6%. The incidence of grade 3-4 neutropenia was 40.2% and only 1 patient was reported with febrile neutropenia. Severe thrombocytopenia and anemia occurred in 0.9% and 4.7% of patients, respectively. Peripheral neuropathy was frequent, but never severe, only 5 (4.7%) patients recorded had more than grade 1 toxicity. Patients with ER- disease had superior pCR rate than ER+ patients (32.6% vs. 9.7%, P=0.005). Patients with PR- disease had higher pCR rate than PR+ patients (30.6% vs. 10.2%, P=0.010). pCR rate was 33.3% (8/24) and 15.5% (13/84) in HER2+ and HER2- patients. Furthermore, We used ER, PR and HER2 status to construct molecular classification of breast cancer, patients classified with Luminal A (HR+/HER2-) subtype had the lowest pCR rate, which was 8.3% less than 22.2% in Luminal B (HR+/HER2+), 33.3% in triple-negative (HR-/HER2-) and 40.0% in HER2 positive (HR-/HER2+) subtype patients, P=0.017.Conclusions: Weekly PCb regimen was very active and tolerable as NCT for breast cancer. ER-, PR-, HER2+ and triple negative breast cancer were more likely to achieve pCR. This weekly PCb regimen should consider as a reasonable non-anthracycline-containing option in NCT setting of breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1099.

Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma

Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study.

A Phase II Trial of Weekly Paclitaxel and High-Dose 5-Fluorouracil Plus Leucovorin in Patients with Chemotherapy-Pretreated Metastatic Breast Cancer.

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.

Weekly Paclitaxel Improved Pathological Response of Primary Chemotherapy Compared with Standard 3 Weeks Schedule

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.

Final Result of Non-Anthracycline Containing Weekly Paclitaxel Plus Carboplatin Regimen As Neoadjuvant Chemotherapy for Breast Cancer.

[A Multicenter Randomized Clinical Trial of Weekly Paclitaxel and Carboplatin Vs Three Weeks Paclitaxel and Carboplatin As First Line Chemotherapy in Epithelial Ovarian Cancer].

Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

A Phase Ii Study of Weekly Nanoparticle Albumin-Bound Paclitaxel Combined with Cisplatin in Patients with Metastatic Breast Cancer

A Clinical Study on the Safety of Weekly Paclitaxel /Docetaxel Combined with Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer

[A Phase II Prospective Randomized Controlled Trial of Weekly Paclitaxel Combined with S-1 or Fluorouracil for Advanced Gastric Carcinoma].

[Neoadjuvant Chemotherapy with Docetaxel Plus Epirubicin for Locally Advanced Breast Cancer: a Multi-Center Phase II Study].

Weekly Paclitaxel and High-Dose 5-Fluorouracil Plus Leucovorin in Hormone-Refractory Prostate Cancer: in Vitro Combined Effects and a Phase II Trial

Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer

Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer

Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group

Improved Local Control by Surgery and Paclitaxel-Based Chemoradiation for Esophageal Squamous Cell Carcinoma: Results of a Retrospective Non-Randomized Study.

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)